DOI:
10.1055/s-00000007
Aktuelle Urologie
Issue 06 ·
Volume 51 ·
December 2020
DOI: 10.1055/s-010-49816
eFirst
Issue
Most Read
Referiert und kommentiert
510
512
516
518
520
522
524
526
528
Rexer, H.;
Grimm, M.-O.;
Steiner, T.:
Tipps und Tricks
530
Recht in der Praxis
532
Uroquiz
535
Wiedemann, Andreas;
Schochtow, Sergej:
Purulent urethral fluorine after cystectomy for radiogenic cystitis
Danksagung
537
Editorial
545
Merseburger, Axel:
Prostate cancer – where is the journey going?
Übersicht
547
Höfner, Thomas:
Antihormonal therapy of prostate cancer – treatment indication and cardiovascular risk profile – advantage for GnRH antagonists?
552
Hammerer, Peter;
Grohmann, Walther;
Merseburger, Axel S.:
Current data on the target value of testosterone lowering and the associated research since the first administration of LHRH (GnRH) analogues to patients 40 years ago
557
Miller, Kurt:
Sequential therapy for asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer
572
Miller, Kurt;
Bergmann, Lothar;
Doehn, Christian;
Grünwald, Viktor;
Gschwend, Jürgen E.;
Ivanyi, Philipp;
Keilholz, Ulrich;
Kuczyk, Markus A.:
Interdisciplinary recommendations for the treatment of advanced metastatic renal cell carcinoma
582
Thelen, P.;
Taubert, H.;
Duensing, S.;
Kristiansen, G.;
Merseburger, A. S.;
Cronauer, M. V.:
The impact of the androgen receptor splice variant AR-V7 on the prognosis and treatment of advanced prostate cancer
Erratum
551
Höfner, Thomas:
Antihormonal therapy of prostate cancer – treatment indication and cardiovascular risk profile – advantage for GnRH antagonists?
Originalarbeit
562
Merseburger, Axel S.;
Rüssel, Christoph;
Belz, Hanjo;
Spiegelhalder, Philipp;
Feyerabend, Susan;
Tran, Nguyen;
Kruetzfeldt, Katrin;
Baurecht, Werner;
Bögemann, Martin:
Early- vs. late-onset treatment using abiraterone acetate plus prednisone in chemo-naïve, asymptomatic or mildly symptomatic patients with metastatic CRPC after androgen deprivation therapy
Operative Techniken
593
Müller, Stefan C.;
Rogenhofer, Sebastian: